// App-Quantinova.ai

565 : Tumor infiltrating lymphocytes (TILs) in breast cancer (BC) patients with progressive disease during neoadjuvant chemotherapy (NAT).

Researchers

Presenter

  • Jacques Raphael

Principal Investigators

  • Sharon Nofech-Mozes

  • Thivaher Paramsothy

  • Nim Li

  • Sonal Gandhi

Medical Centers

  • Sunnybrook Odette Cancer Centre, University of Toronto, Department of Medicine, Division of Medical Oncology, Toronto, ON, Canada

  • Sunnybrook Health Sciences Centre, Department of Pathology, Toronto, ON, Canada

  • Sunnybrook Health Sciences Centre, Department of Medicine, Division of Medical Oncology, Toronto, ON, Canada

  • Sunnybrook Research Institute, Toronto, ON, Canada

  • Sunnybrook Odette Cancer Centre, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • Umirolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved